Skip to main content
Category

COVID-19

cortney boccardi
In COVID-19

What Your Health Labs Are NOT Doing, and How Precision Genetics Is Taking Care of You

Precision Genetics has partnered with many strong, dedicated health systems to be part of the impact on fighting the COVID-19 pandemic this year. Precision Genetics is doing what we can to lessen what is a high demand with COVID right now. Everyone is seeing spikes and supply shortages. Precision has not encountered a supply shortage or a backlog because of our unique operational efficiency.

Our latest venture brings our story to national news media so others can hear how they can benefit from fast, accurate and reliable testing and results in a time of shortages and long waits.  You can find us in Mediaplanet’s Fighting the Flu campaign, out today!

Learn More

cortney boccardi
In COVID-19

Precision Genetics Launches Combination Test to Detect COVID-19 and the Flu

Precision Genetics has developed a test that can detect the presence of both COVID-19 and the Flu (Influenza A and B) from a single sample.  The combination makes diagnosing the cause of a patient’s symptoms clear for patients and providers.  “By utilizing our high-complexity laboratory and testing methods, we can quickly and accurately distinguish between these viral infections,” said Nate Wilbourne, founder and CEO of Precision Genetics.

 

Learn More

cortney boccardi
In COVID-19

Precision Genetics Advances COVID-19 Testing by Adding Saliva Collection Under Existing EUA

Precision Genetics has added saliva collection to its existing portfolio of validated COVID-19 testing options under the existing Food and Drug Administration emergency use authorization. This advancement comes at a time when people have become increasingly more resistant to the idea of nasopharyngeal (NP) swab testing. Saliva collection requires the patient to expel their saliva into a tube, making it far less invasive than the standard nasopharyngeal collection method.

Learn More

cortney boccardi
In COVID-19

SCRA Announces a $250,000 SC Launch, Inc. Investment in Precision Genetics.

SCRA has provided a $250,000 investment in Precision Genetics through SC Launch to help the company expand its processing of COVID-19 test kits.

“SCRA: South Carolina Research Authority and #SCLaunchInc. stepped up and provided financial commitment and strategic support for us to expedite our efforts. We are desperately trying to serve our community in this time of need, and we are very grateful for the support from SCRA and SC Launch, Inc.” said Nate Wilbourne, CEO of Precision Genetics.

Learn more here.

Close Menu